Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk is providing direct-to-patient delivery of Wegovy ® (semaglutide ... those with commercial insurance but no coverage for obesity medications) can receive Wegovy (2.5mg, 0.5mg ...

Novo Nordisk is expanding its reach in the obesity medicines market by making its blockbuster weight loss drug Wegovy available directly to certain patients for more than half off the product’s ...

Novo Nordisk is cutting the price of its weight-loss drug, Wegovy, and selling it through a direct-to-patient online pharmacy ...